골이식재 시장 : 규모, 점유율, 성장, 업계 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of bone graft substitutes Market

The global bone graft substitutes market was valued at USD 4.29 billion in 2025 and is projected to grow to USD 4.55 billion in 2026, reaching USD 7.64 billion by 2034, exhibiting a CAGR of 6.68% during the forecast period (2026-2034). The growth of this market is primarily driven by the increasing prevalence of bone-related disorders, rising orthopedic procedures, and growing demand for advanced biomaterials.

Bone graft substitutes are biologically compatible materials used as alternatives to autologous bone grafts. These include allografts, synthetic materials, demineralized bone matrix (DBM), and xenografts. Their advantages, such as reduced donor site complications, improved safety, and enhanced bone healing capabilities, have significantly boosted their adoption.

Market Dynamics

Key Growth Drivers

One of the major drivers of the market is the increasing number of orthopedic and spinal surgeries globally. Bone graft substitutes are widely used in spinal fusion, trauma repair, and joint reconstruction procedures. Additionally, the rising incidence of bone diseases such as infections, tumors, and arthritis is accelerating demand.

Technological advancements have also played a crucial role. The development of synthetic grafts using materials like calcium phosphate and hydroxyapatite has improved treatment outcomes and reduced complications. These materials closely mimic natural bone structure, enhancing their acceptance among healthcare providers.

Another key factor is the growing application of bone graft substitutes in dental implants, where they help in improving jawbone structure and supporting implant placement.

Market Restraints

Despite strong growth, the market faces certain challenges. Clinical limitations such as incomplete bone formation, risk of infection, and adverse tissue reactions can hinder adoption. Additionally, product recalls and regulatory concerns have impacted the reputation of some manufacturers, limiting market expansion.

Market Segmentation Analysis

By Type

The market is segmented into allograft, synthetic, DBM, and xenograft.

• The synthetic segment dominated the market, accounting for the largest share in 2026 due to its biocompatibility and lower risk of complications.
• Allografts are expected to grow steadily due to their effectiveness in treatment outcomes.
• DBM holds a significant share due to increased usage in trauma and spine surgeries.
• Xenografts are gaining traction with advancements in processing technologies.

By Application

Applications include spinal fusion, joint reconstruction, and others.

• Spinal fusion emerged as the leading segment, accounting for the largest share in 2026, driven by the increasing number of spine-related disorders.
• Joint reconstruction is also witnessing strong growth due to rising cases of arthritis and joint damage.

By End-user

The market is categorized into hospitals, specialty clinics, and others.

• Hospitals held the largest market share in 2026, supported by high patient inflow and availability of advanced surgical infrastructure.
• Specialty clinics are expected to grow rapidly due to expanding healthcare access in developing regions.

Regional Insights

North America

North America dominated the market with a 46.34% share in 2025, valued at USD 1.99 billion, and is projected to reach USD 2.11 billion in 2026. Growth is driven by high surgical volumes, advanced healthcare infrastructure, and strong presence of key players.

Europe

Europe accounted for USD 1.12 billion in 2025 and is expected to reach USD 1.18 billion in 2026. Favorable reimbursement policies and increasing R&D investments are supporting regional growth.

Asia Pacific

Asia Pacific generated USD 0.83 billion in 2025 and is projected to reach USD 0.89 billion in 2026. Rapid growth is attributed to rising geriatric population, increasing healthcare investments, and growing awareness of advanced treatments.

Middle East & Africa and Latin America

These regions accounted for smaller shares but are expected to grow steadily due to improving healthcare infrastructure and rising incidence of bone injuries.

Competitive Landscape

Key players in the market include leading global companies with strong product portfolios and geographic presence. These companies focus on strategic initiatives such as product launches, partnerships, and acquisitions to strengthen their market position. Continuous innovation, especially in synthetic grafts, remains a major competitive factor.

Conclusion

The global bone graft substitutes market is poised for steady growth, increasing from USD 4.29 billion in 2025 to USD 7.64 billion by 2034. The market expansion is driven by rising orthopedic procedures, technological advancements, and growing demand for minimally invasive and effective treatment solutions.

While challenges such as clinical limitations and regulatory concerns persist, ongoing innovation and increasing adoption of synthetic substitutes are expected to overcome these barriers. Additionally, expanding applications in dental and spinal procedures, along with growing healthcare investments in emerging economies, will further accelerate market growth.

Segmentation

By Type

• Allograft
• Demineralized Bone Matrix (DBM)
• Synthetic
  • Polymer
  • Ceramic
  • Hydroxypaptite
  • Beta TCP
  • Others
• Xenograft

By Application

• Spinal Fusion
• Joint Reconstruction
• Foot & Ankle
• Others

By End-user

• Hospitals
• Specialty Clinics
• Others

By Geography

• North America (By Type, By Application, By End-user, and By Country)
  • U.S. (By Application)
  • Canada (By Application)
• Europe (By Type, By Application, By End-user, and By Country/Sub-region)
  • Germany (By Application)
  • U.K. (By Application)
  • France (By Application)
  • Italy (By Application)
  • Russia (By Application)
  • Rest of Europe (By Application)
• Asia Pacific (By Type, By Application, By End-user, and By Country/Sub-region)
  • China (By Application)
  • India (By Application)
  • Japan (By Application)
  • Australia (By Application)
  • Rest of Asia Pacific (By Application)
• Latin America (By Type, By Application, By End-user, and By Country/Sub-region)
  • Brazil (By Application)
  • Mexico (By Application)
  • Rest of Latin America (By Application)
• Middle East & Africa (By Type, By Application, By End-user, and By Country/Sub-region)
  • South Africa (By Application)
  • GCC (By Application)
  • Rest of Middle East & Africa (By Application)

Table of Content

1. Introduction

• 1.1. Market Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Recent Industry Developments Such as Mergers & Acquisitions
• 4.2. Insights on Funding Scenario Pertaining to Research and Development of Bone Grafts Substitutes
• 4.3. Industry Background Pertaining to Bone Graft Substitutes
• 4.4. New Product Launches
• 4.5. Impact of COVID-19 on Bone Graft Substitutes Market

5. Global Bone Graft Substitutes Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Allograft
  • 5.1.2. Demineralized Bone Matrix (DBM)
  • 5.1.3. Synthetic
    • 5.1.3.1. Polymers
    • 5.1.3.2. Ceramic
      • 5.1.3.2.1. Hydroxyapatite
      • 5.1.3.2.2. Beta TCP
      • 5.1.3.2.3. Others
  • 5.1.4. Xenograft
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Spinal Fusion
  • 5.2.2. Joint Reconstruction
  • 5.2.3. Foot & Ankle
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals
  • 5.3.2. Specialty Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Bone Graft Substitutes Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Allograft
  • 6.1.2. Demineralized Bone Matrix (DBM)
  • 6.1.3. Synthetic
    • 6.1.3.1. Polymers
    • 6.1.3.2. Ceramic
      • 6.1.3.2.1. Hydroxyapatite
      • 6.1.3.2.2. Beta TCP
      • 6.1.3.2.3. Others
  • 6.1.4. Xenograft
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Spinal Fusion
  • 6.2.2. Joint Reconstruction
  • 6.2.3. Foot & Ankle
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals
  • 6.3.2. Specialty Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Application
  • 6.4.2. Canada
    • 6.4.2.1. By Application

7. Europe Bone Graft Substitutes Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Allograft
  • 7.1.2. Demineralized Bone Matrix (DBM)
  • 7.1.3. Synthetic
    • 7.1.3.1. Polymers
    • 7.1.3.2. Ceramic
      • 7.1.3.2.1. Hydroxyapatite
      • 7.1.3.2.2. Beta TCP
      • 7.1.3.2.3. Others
  • 7.1.4. Xenograft
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Spinal Fusion
  • 7.2.2. Joint Reconstruction
  • 7.2.3. Foot & Ankle
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. Germany
    • 7.4.1.1. By Application
  • 7.4.2. U.K.
    • 7.4.2.1. By Application
  • 7.4.3. France
    • 7.4.3.1. By Application
  • 7.4.4. Italy
    • 7.4.4.1. By Application
  • 7.4.5. Russia
    • 7.4.5.1. By Application
  • 7.4.6. Rest of Europe
    • 7.4.6.1. By Application

8. Asia Pacific Bone Graft Substitutes Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Allograft
  • 8.1.2. Demineralized Bone Matrix (DBM)
  • 8.1.3. Synthetic
    • 8.1.3.1. Polymers
    • 8.1.3.2. Ceramic
      • 8.1.3.2.1. Hydroxyapatite
      • 8.1.3.2.2. Beta TCP
      • 8.1.3.2.3. Others
  • 8.1.4. Xenograft
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Spinal Fusion
  • 8.2.2. Joint Reconstruction
  • 8.2.3. Foot & Ankle
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals
  • 8.3.2. Specialty Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. China
    • 8.4.1.1. By Application
  • 8.4.2. India
    • 8.4.2.1. By Application
  • 8.4.3. Japan
    • 8.4.3.1. By Application
  • 8.4.4. Australia
    • 8.4.4.1. By Application
  • 8.4.5. Rest of Asia Pacific
    • 8.4.5.1. By Application

9. Latin America Bone Graft Substitutes Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Allograft
  • 9.1.2. Demineralized Bone Matrix (DBM)
  • 9.1.3. Synthetic
    • 9.1.3.1. Polymers
    • 9.1.3.2. Ceramic
      • 9.1.3.2.1. Hydroxyapatite
      • 9.1.3.2.2. Beta TCP
      • 9.1.3.2.3. Others
  • 9.1.4. Xenograft
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Spinal Fusion
  • 9.2.2. Joint Reconstruction
  • 9.2.3. Foot & Ankle
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals
  • 9.3.2. Specialty Clinics
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Application
  • 9.4.2. Mexico
    • 9.4.2.1. By Application
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Application

10. Middle East & Africa Bone Graft Substitutes Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Allograft
  • 10.1.2. Demineralized Bone Matrix (DBM)
  • 10.1.3. Synthetic
    • 10.1.3.1. Polymers
    • 10.1.3.2. Ceramic
      • 10.1.3.2.1. Hydroxyapatite
      • 10.1.3.2.2. Beta TCP
      • 10.1.3.2.3. Others
  • 10.1.4. Xenograft
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Spinal Fusion
  • 10.2.2. Joint Reconstruction
  • 10.2.3. Foot & Ankle
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By End-user
  • 10.3.1. Hospitals
  • 10.3.2. Specialty Clinics
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. South Africa
    • 10.4.1.1. By Application
  • 10.4.2. GCC
    • 10.4.2.1. By Application
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Application

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Medtronic PLC
    • 11.2.1.1. Overview
    • 11.2.1.2. Product
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. DePuy Synthes Companies (Johnson & Johnson Services, Inc.)
    • 11.2.2.1. Overview
    • 11.2.2.2. Product
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Stryker
    • 11.2.3.1. Overview
    • 11.2.3.2. Product
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Zimmer Biomet
    • 11.2.4.1. Overview
    • 11.2.4.2. Product
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Smith & Nephew plc
    • 11.2.5.1. Overview
    • 11.2.5.2. Product
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. SeaSpine
    • 11.2.6.1. Overview
    • 11.2.6.2. Product
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. AlloSource
    • 11.2.7.1. Overview
    • 11.2.7.2. Product
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Bioventus
    • 11.2.8.1. Overview
    • 11.2.8.2. Product
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. MTF Biologics
    • 11.2.9.1. Overview
    • 11.2.9.2. Product
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Orthofix Holdings, Inc.
    • 11.2.10.1. Overview
    • 11.2.10.2. Product
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)